A year after a major layoff round at its Allergan headquarters in California, AbbVie is making more edits to its workforce with a new round of 85 layoffs. | The layoffs at AbbVie's Irvine, California ...
The TROP2 battle in first-line triple-negative breast cancer has officially kicked off. | A three-way battle among TROP2 ADCs ...
AbbVie's 85 layoffs are tied to its Allergan Aesthetics headquarters in California, while Novartis is cutting more staff at its U.S. HQ in New Jersey.
A web of mail-order pharmacies, wholesalers and patient services groups connected to the self-styled largest Pentecostal ...
Gilead Sciences and the World Health Organization (WHO) are doubling down on a pact to eliminate deadly parasitic disea | ...
After the drug’s local license holder called for a brief pause in new patient starts last week, doctors in Japan can once ...
Healthcare agencies remain at the forefront of pharmaceutical marketing, but new technologies and shifting political dynamics ...
Bristol Myers Squibb is the latest large pharma company to be making a major bet on artificial intelligence, announcing a sweeping agreement with Anthropic to deploy its AI tool Claude as the “shared ...
After some six years at the post, Amgen’s finance chief is telegraphing his exit from the California pharma by early next ...
An Ipsen-commissioned survey has identified widespread problems with the transition from pediatric to adult healthcare, ...
Even as a new drug pricing specter rears its head in President Donald Trump’s “Most Favored Nation” policies, drugmakers ...
Gilead Sciences has broadened its partnership with Korean manufacturer Yuhan, agreeing to a 210 billion Korean won ($140 million) supply deal for active pharmaceutical ingredients (API) for an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results